Skip to main content

Table 2 Baseline disease parameters overall and by Work Time Loss Category

From: Association between work time loss and quality of life in patients with Herpes Zoster: a pooled analysis of the MASTER studies

Variable

Work Time Loss Category

Overallb

p-value

Work Time Lossa

No Work Time Loss

Total n, %

247 (57.7)

147 (34.3)

428

-

Time from HZ onset, days

  n

247

147

427

 

 Mean (SD)

124.2 (458.3)

79.6 (284.2)

128.6 (476.6)

<0.001

Time from HZ onset - categorical, n (%)

 Incident

74 (30.0)

65 (44.2)

154 (36.0)

 

 Prevalent

173 (70.0)

82 (55.8)

273 (63.8)

0.004

 Not available

0 (0.0)

0 (0.0)

1 (0.2)

 

Pain before rash appearance, n (%)

 Yes

156 (63.2)

89 (60.5)

260 (60.7)

 

 No

79 (32.0)

52 (35.4)

146 (34.1)

0.520

 Not available

12 (4.9)

6 (4.1)

22 (5.1)

 

Average pain score before rash appearancec

  n

155

88

258

 

 Mean (SD)

4.9 (2.6)

4.4 (2.5)

4.7 (2.6)

0.148

Worst pain before rash appearancec

  n

154

86

255

 

 Mean (SD)

6.4 (2.6)

5.8 (2.5)

6.2 (2.6)

0.057

Pain since rash appearance, n (%)

 Yes

222 (89.9)

130 (88.4)

376 (87.9)

 

 No

14 (5.7)

12 (8.2)

33 (7.7)

0.349

 Not available

11 (4.5)

5 (3.4)

19 (4.4)

 

Average pain since rash appearancec

  n

222

129

375

 

 Mean (SD)

5.6 (2.3)

4.7 (2.2)

5.3 (2.3)

0.002

Worst pain since rash appearancec

  n

221

128

373

 

 Mean (SD)

7.6 (2.3)

6.5 (2.5)

7.2 (2.5)

<0.001

Pain in the last 24 hs

 Yes

224 (90.7)

126 (85.7)

380 (88.8)

 

 No

23 (9.3)

20 (13.6)

47 (11.0)

0.178

 Not available

0 (0.0)

1 (0.7)

1 (0.2)

 

Average pain in last 24 hc

  n

224

126

380

 

 Mean (SD)

4.5 (2.5)

4.0 (2.3)

4.3 (2.4)

0.062

Worst pain in last 24 hc

  n

220

124

372

 

 Mean (SD)

6.2 (2.6)

5.4 (2.6)

5.9 (2.6)

0.004

Worst pain score category, n (%)d

 Mild

43 (17.4)

35 (23.8)

83 (19.4)

 

 Moderate

91 (36.8)

55 (37.4)

161 (37.6)

0.041

 Severe

86 (34.8)

33 (22.4)

127 (29.7)

 

 Not available

27 (10.9)

24 (16.3)

57 (13.3)

 

Severity of rash (number of lesions), n (%)

 No rash

56 (22.7)

18 (12.2)

84 (19.6)

 

 Mild (1–20)

107 (43.3)

86 (58.5)

207 (48.4)

 

 Moderate (21–50)

49 (19.8)

24 (16.3)

77 (18.0)

0.014

 Severe (>50)

35 (14.2)

18 (12.2)

59 (13.8)

 

 Not available

0 (0.0)

1 (0.7)

1 (0.2)

 

Impaired immune statuse

 Yes

18 (7.3)

9 (6.1)

29 (6.8)

 

 No

229 (92.7)

138 (93.9)

399 (93.2)

0.658

Presence of HZ complication

 Yes

80 (32.4)

40 (27.2)

136 (31.8)

 

 No

166 (67.2)

107 (72.8)

291 (68.0)

0.269

 Not available

1 (0.4)

0 (0.0)

1 (0.2)

 

Medication for HZ

 Yes

23 (9.3)

24 (16.3)

51 (11.9)

 

 No

224 (90.7)

123 (83.7)

377 (88.1)

0.038

  1. SD standard deviation, HZ Herpes Zoster, CIS carcinoma in situ, HIV human immunodeficiency virus, AIDS acquired immune deficiency syndrome
  2. aPatients with Work Time Loss were defined as those who reported missing work due to their shingles episode (entire day or part of a day) at baseline, as assessed by the WPQ
  3. b34 patients did not have information on Work Time Loss Category
  4. cMeasured on an 11 point Likert scale which ranges from “no pain” (0) to “pain as bad as you can imagine” (11)
  5. dWorst pain score categories are based on the ZPBI “worst pain in the last 24 h” scores: mild worst pain = ZBPI scores 0- ≤ 3; moderate worst pain = ZBPI scores 4- ≤ 7; severe worst pain = ZBPI score ≥8
  6. eDefined as: use of high dose oral corticosteroids, invasive cancers (with the exception of CIS and non-melanoma skin cancer), HIV infection/ AIDS, immune deficiency, chemotherapy for cancer, prior or concurrent immunosuppressive therapy, and therapy for organ transplant
Back to article page

Health and Quality of Life Outcomes

ISSN: 1477-7525

Contact us